HUTCHMED China Ltd (HCM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HUTCHMED China Ltd (HCM) has a cash flow conversion efficiency ratio of -0.029x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-36.45 Million) by net assets (GBX1.24 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
HUTCHMED China Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how HUTCHMED China Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
HUTCHMED China Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED China Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ECM Libra Financial Group Bhd
KLSE:2143
|
0.020x |
|
Ttbio Corp.
TWO:6493
|
-0.003x |
|
Alumexx N.V.
AS:ALX
|
0.571x |
|
Four Seasons Education Cayman
NYSE:FEDU
|
N/A |
|
Global Uranium and Enrichment Ltd
AU:GUE
|
-0.029x |
|
PJX Resources Inc
V:PJX
|
-0.754x |
|
CVD Equipment Corporation
NASDAQ:CVV
|
0.053x |
|
431190
KQ:431190
|
-0.009x |
Annual Cash Flow Conversion Efficiency for HUTCHMED China Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX771.85 Million | GBX497.00K | 0.001x | -99.78% |
| 2023-12-31 | GBX743.39 Million | GBX219.26 Million | 0.295x | +169.93% |
| 2022-12-31 | GBX636.87 Million | GBX-268.60 Million | -0.422x | -114.67% |
| 2021-12-31 | GBX1.04 Billion | GBX-204.22 Million | -0.196x | -64.27% |
| 2020-12-31 | GBX518.95 Million | GBX-62.07 Million | -0.120x | +53.75% |
| 2019-12-31 | GBX312.90 Million | GBX-80.91 Million | -0.259x | -224.54% |
| 2018-12-31 | GBX412.25 Million | GBX-32.85 Million | -0.080x | -332.07% |
| 2017-12-31 | GBX484.97 Million | GBX-8.94 Million | -0.018x | +60.68% |
| 2016-12-31 | GBX204.06 Million | GBX-9.57 Million | -0.047x | +48.90% |
| 2015-12-31 | GBX102.28 Million | GBX-9.38 Million | -0.092x | -182.34% |
| 2014-12-31 | GBX119.88 Million | GBX13.36 Million | 0.111x | +132.36% |
| 2013-12-31 | GBX104.84 Million | GBX5.03 Million | 0.048x | -74.38% |
| 2012-12-31 | GBX83.65 Million | GBX15.66 Million | 0.187x | +178.34% |
| 2011-12-31 | GBX77.33 Million | GBX5.20 Million | 0.067x | +123.36% |
| 2010-12-31 | GBX68.81 Million | GBX-19.82 Million | -0.288x | -286.53% |
| 2009-12-31 | GBX75.30 Million | GBX11.63 Million | 0.154x | +191.37% |
| 2008-12-31 | GBX84.43 Million | GBX-14.27 Million | -0.169x | -91.86% |
| 2007-12-31 | GBX97.61 Million | GBX-8.60 Million | -0.088x | -166.27% |
| 2006-12-31 | GBX109.98 Million | GBX-3.64 Million | -0.033x | -106.81% |
| 2005-12-31 | GBX-28.01 Million | GBX-13.60 Million | 0.485x | -- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more